A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

1. Laubach, J.P.
2. Moslehi, J.J.
3. Francis, S.A.
4. San Miguel, J.F.
5. Sonneveld, P.
6. Orlowski, R.Z.
7. Moreau, P.
8. Rosiñol, L.
9. Faber, E.A.
10. Voorhees, P.
11. Mateos, M.-V.
12. Marquez, L.
13. Feng, H.
14. Desai, A.
15. van de Velde, H.
16. Elliott, J.
17. Shi, H.
18. Dow, E.
19. Jobanputra, N.
20. Esseltine, D.-L.
21. Niculescu, L.
22. Anderson, K.C.
23. Lonial, S.
24. Richardson, P.G.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1111/BJH.14708 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus